Steve Nguyen

TL;DR: It is demonstrated that the chimpanzee not only developed protective immunity to the homologous type 1a RNA after rechall challenge by IHGI but was also protected from chronic HCV infection after sequential rechallenge with 100 50% chimpanzee infectious doses of a heterologoustype 1a (H77) and 1b (HC-J4) whole-virus inoculum.

TL;DR: The data suggest that the HCV polyprotein delivered with adjuvants induces broad B- and T-cell responses and could be a vaccine candidate against HCV.

TL;DR: The results indicate that MEFA-6 exposes all of the major immunogenic epitopes from the seven functional regions of the HCV genome, and its excellent sensitivity and specificity for the detection of clinical seroconversion are demonstrated by this assay.

TL;DR: An HCV antibody assay that employs a conformational protein, NS3NS4a PI (with functional protease and helicase activities), and a linear fusion protein, multiple-epitope fusion antigen 7.1 or 7.2 may have the potential to replace current HCV immunoassays for better sensitivity.

TL;DR: It was found that early anti‐HBe seroconversion antibodies appear to be conformational, whereas later serconversion, more typically associated with the clearance of HBeAg, is characterized by the presence of antibodies to the linear H beAg epitopes.